Clinical trials: PET Positive
Solitary Pulmonary Nodules, Lung Cancer
Plasma Metabolomics as a Tool to Distinguish PET-positive Malignant From PET-positive Benign Nodules
Positron emission tomography-computed tomography (PET-CT) is an important technique in lung cancer staging, where almost no lung lesion goes undetected.
- Trial name
- NCT07087080
- Testing
- Blood sampling
- Where
- Belgium
- Volunteers
- 350 people
- Sponsor
- Hasselt University
Thyroid Cancer
Thyroid Cancer and (FDG)PET/CT Scan
Background and Rational (Introduction) Differentiated thyroid carcinoma (DTC) have favorable prognosis. Overall 10-year survival is 93% for papillary carcinoma, and 85% for follicular carcinoma(1).
- Trial name
- NCT04128631
- Volunteers
- 35 people
- Sponsor
- Assiut University
Lymphoma
Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00907036
- Testing
- alemtuzumab, donor lymphocytes, cyclosporine
- Volunteers
- 49 people
- Sponsor
- Cancer Research UK
Classical Hodgkin Lymphoma, Hodgkin Lymphoma (Category)
OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy
This is a prospective, multi-center, open-label, phase II clinical trial, aims to assess the effectiveness of the combination ACVD (Adriamycin, Cyclophosphamide, Vinblastine and Dacarbazine) and BV (Brentuximab Vedotin) in PET-2…
- Conditions
- Classical Hodgkin Lymphoma, Hodgkin Lymphoma (Category), Hodgkin Disease, Hodgkin Lymphoma
- Trial name
- (Optimist) (NCT03527628)
- Testing
- Adriamycin, Cyclophosphamide, Vinblastine
- Where
- Saudi Arabia
- Volunteers
- 220 people
- Sponsor
- King Abdullah International Medical Research Center
Medullary Thyroid Carcinoma
Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC
This study explores the clinical application of 68Ga-DOTA-CCK-FS PET/CT in detecting cholecystokinin-2 receptor (CCK-2R)-positive tumors, particularly medullary thyroid cancer (MTC) and other malignancies. Led by Prof.
- Trial name
- NCT07138716
- Testing
- 68Ga-DOTA-CCK-FS PET/CT
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Luo Yaping
Meningioma, Metastatic Well Differentiated Neuroendocrine Neoplasm
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors.
- Conditions
- Meningioma, Metastatic Well Differentiated Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1, Neuroendocrine Neoplasm
- Trial name
- NCT03001349
- Testing
- Computed Tomography, Gallium Ga 68-Edotreotide, Positron Emission Tomography
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Gastric Cancer (GC)
The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies
The purpose of this study is to develop and clinically evaluate 89Zr-labeled HER2-targeted antibodies in diagnosis and screening of HER2-positive cancer patients.
- Conditions
- Breast Cancer, Gastric Cancer (GC), Urothelial Carcinoma (UC)
- Trial name
- NCT07023861
- Testing
- 18F-FDG, 89Zr-LNCab190, 89Zr-LNCab002
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Affiliated Hospital of Jiangnan University
Neuroendocrine Tumors, Carcinoid Tumors
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma, Medulloblastoma
- Trial name
- GA-68 (NCT01619865)
- Testing
- 68Ga-DOTATOC PET/CT
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- Sue O'Dorisio
Hodgkin Lymphoma
Early Chemotherapy Intensification in Interim-Positron Emission Tomography (PET) Positive Hodgkin Lymphoma
Early interim-PET after two courses of chemotherapy is a powerful outcome predictor in advanced-stage Hodgkin Lymphoma (HL) patients treated with adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine (ABVD).
- Trial name
- NCT00877747
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- Ospedale Santa Croce-Carle Cuneo
Adult Medulloblastoma, Childhood Medulloblastoma
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
This clinical trial studies gallium Ga 68-edotreotide positron emission tomography (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosing patients with…
- Conditions
- Adult Medulloblastoma, Childhood Medulloblastoma, Neuroblastoma, Neuroendocrine Tumor
- Trial name
- NCT01869725
- Testing
- gallium Ga 68-edotreotide, positron emission tomography/computed tomography, indium In 111 pentetreotide
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Sue O'Dorisio
Neuroendocrine Tumors
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
A [68]Ga-HA-DOTATATE PET/CT or PET/MRI scan is a nuclear medicine test used to create pictures of the whole body that will show where somatostatin receptors are found, including on tumours.
- Trial name
- NCT03145857
- Testing
- [68]Ga-HA-DOTATATE
- Where
- Canada
- Volunteers
- 634 people
- Sponsor
- AHS Cancer Control Alberta